Correction: Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial
Main Authors: | Farastuk Bozorgmehr, Inn Chung, Petros Christopoulos, Johannes Krisam, Marc A. Schneider, Lena Brückner, Daniel Wilhelm Mueller, Michael Thomas, Stefan Rieken |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-08-01
|
Series: | BMC Cancer |
Online Access: | https://doi.org/10.1186/s12885-023-11270-x |
Similar Items
-
Long-Term Results of Postoperative Hypofractionated Accelerated Breast and Lymph Node Radiotherapy (HypoAR) with Hypofractionated Boost
by: Ioannis M. Koukourakis, et al.
Published: (2021-09-01) -
Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC
by: Christian Wilhelm Langberg, et al.
Published: (2023-07-01) -
Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC
by: Johan F. Vansteenkiste, MD, PhD, et al.
Published: (2024-03-01) -
Pneumonitis During Durvalumab Consolidation Therapy Affects Survival in Stage III NSCLC
by: Yuhei Kinehara, MD, PhD, et al.
Published: (2023-11-01) -
Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLC
by: Tomoki Kuge, MD, et al.
Published: (2023-05-01)